Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells-Reference-Cited by-同舟云学术

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells

Published:2019-10 Issue:4 Volume:76 Page:430-434
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Kettunen Kimmo,Boström Peter J.,Lamminen Tarja,Heinosalo Taija,West Gun,Saarinen Irena,Kaipio Katja,Rantala Juha,Albanese Chris,Poutanen Matti,Taimen Pekka

Publisher

Elsevier BV

Subject

Urology

Reference11 articles.

1. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer;Witjes;Eur Urol,2017

2. Tumor evolution and drug response in patient-derived organoid models of bladder cancer;Lee;Cell,2018

3. Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer;Saeed;Eur Urol,2017

4. Use of reprogrammed cells to identify therapy for respiratory papillomatosis;Yuan;N Engl J Med,2012

5. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells;Sette;Int J Cancer,2018

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential benefits of concomitant statins treatment in patients with non‐muscle‐invasive bladder cancer;BJU International;2024-09-10

2. Bioprinted research models of urological malignancy;Exploration;2024-02-20

3. NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer;Cell Reports;2023-08

4. Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation;Cells;2023-06-24

5. 3D Tumor Models in Urology;International Journal of Molecular Sciences;2023-03-25